Best Practice of Stability-Indicating HPLC Method Development
E-Separation Solutions
Tuesday?s morning session, ?Best Practice of Stability-Indicating HPLC Method Development,? was arranged by LCGC contributor Michael W. Dong of Genentech. Dong will begin the session with his opening remarks on the topic promptly at 8:00 a.m.
Tuesday, March 2, 2010
Room 207B
Tuesday’s morning session, “Best Practice of Stability-Indicating HPLC Method Development,” was arranged by LCGC contributor Michael W. Dong of Genentech. Dong will begin the session with his opening remarks on the topic promptly at 8:00 a.m.
Following Dong’s remarks will be a presentation from LCGC’s “LC Troubleshooting” Columnist John W. Dolan, of LC Resources. Dolan’s talk, “Strategies for Developing Robust HPLC Methods,” will surely be of interest to those familiar with his column and informative overall.
Next up is a presentation from Michael Dong along with his colleagues Derrick Yazzie and Nikhil Desai. Their presentation, aptly titled, “A Roadmap and Some New Tools for Rapid HPLC Method Development,” will offer new insights into HPLC method development.
“A Quality-by-Design Approach to Rapid LC Method Development,” will be presented by Richard Verseput, of S-Matrix, along with Graham Shelver. Following their talk, will be Patrick Jansen and Steven Baertschi from Eli Lilly and Company with, “Forced Degradation Studies Supporting Method Development: Best Practice and Limitations.”
Last up on the agenda is a presentation given by Merck & Co, Inc., employees Naijun Wu, Zhong Li, Robert Pascoe, Guangyu Ma, Monica Yang, and Pamela Rizos. Wu will be representing the team during the talk entitled, “Use of Ultra-high Pressure LC for Expediting Method Development and Difficult Separations.” All of the presentations in this session promise to be helpful for those working in the HPLC market.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
